Regeneron provides update on eylea hd® (aflibercept) injection 8 mg supplemental biologics license application

Tarrytown, n.y., april 18, 2025 (globe newswire) -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that the u.s. food and drug administration (fda) has issued a complete response letter (crl) regarding the supplemental biologics license application (sbla) for the addition of extended dosing intervals (up to every 24 weeks) for eylea hd® (aflibercept) injection 8 mg across all approved indications.
REGN Ratings Summary
REGN Quant Ranking